Economic challenges of oncological diseases’ pharmacotherapy
Oncological diseases rank high in the structure of population morbidity and mortality. They entail considerable direct and indirect economic costs. In the past decades, the cost of oncotherapy has increased significantly, which is largely conditioned by high prices of antitumor drugs, which on avera...
Saved in:
| Main Authors: | E. A. Ushkalova, S. K. Zyryanov, I. A. Gopienko |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2020-04-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/343 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacotherapy of Oncological Diseases: Search for New Drugs and Approaches
by: M. V. Belova
Published: (2023-05-01) -
Options to optimize the access to biosimilars: analysis and solutions
by: O. V. Kirsanova, et al.
Published: (2018-05-01) -
INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01) -
INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01) -
Modern concepts of biosimilars in hematology and oncology
by: V. V. Ptushkin
Published: (2014-07-01)